Publications by authors named "R van Vollenhoven"
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays-overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors-fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.
Objective: The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA).
Methods: This study included 341 participants of the Nordic Rheumatic Diseases Strategy Trials and Registries trial with untreated early RA, randomized at baseline into four treatment arms: methotrexate combined with (1) prednisolone, (2) certolizumab, (3) abatacept, or (4) tocilizumab. Follow-up was up to 48 weeks.
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos.
Objective: Evaluate iberdomide efficacy and safety in cutaneous lupus erythematosus (CLE) in a phase 2 study.
Methods: Patients were randomized (2:2:1:2) to iberdomide 0.
Article Synopsis
- - The PRAIRI study examined the impact of early treatment with rituximab (RTX) on individuals at risk for developing rheumatoid arthritis (RA), finding a significant delay in arthritis onset by up to 12 months.
- - In the trial, 78 RA-risk participants received either RTX or a placebo, with their quality of life measured using various questionnaires over a 2-year period.
- - Results indicated that there were no significant improvements in quality of life or perceived disease severity in those treated with RTX compared to the placebo group.